<div id="readability-page-1"><p>TD Cowen analyst Marc Frahm has maintained their bullish  stance on <span>STTK</span> stock, giving a Buy rating today.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Marc Frahm has given his Buy rating due to a combination of factors, most notably the emerging profile of SL-325 and its upcoming data catalysts. He highlights that the Phase 1 healthy volunteer study has finished enrolling all single- and multiple-ascending-dose cohorts, with data on safety, pharmacokinetics and dynamics, receptor occupancy, and immunogenicity expected in the second quarter of 2026, which could validate strong target coverage with low anti-drug antibody formation.</p> <p>He also points to the planned launch of a randomized Phase 2 Crohn’s disease trial in the third quarter of 2026, with the possibility of an additional open-label Phase 2 study in another inflammatory indication that could broaden the opportunity. Combined with preclinical findings that suggest durable DR3 blockade and a potentially differentiated mechanism versus TL1A antibodies, as well as a cash position that supports near-term execution and the prospect of a multi-billion-dollar valuation if the profile is confirmed, these elements underpin his positive stance on Shattuck Labs’ shares.</p> <p>Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Revolution Medicines. According to TipRanks, Frahm has an average return of <span>22.6%</span> and a 52.02% success rate on recommended stocks. </p> <p>In another report released today, Needham also maintained a Buy rating on the stock with a $14.00 price target.</p></div>

STTK

SBIO

LABU

IBBQ

<p>TD Cowen analyst Marc Frahm has maintained a Buy rating on Shattuck Labs (STTK) stock, citing the promising profile of SL-325 and upcoming data catalysts. Key developments include the completion of Phase 1 study enrollment, with safety and pharmacokinetics data expected in Q2 2026, and a planned Phase 2 trial for Crohn’s disease in Q3 2026. Preclinical findings suggest a strong potential for DR3 blockade, supporting a multi-billion-dollar valuation. Needham also issued a Buy rating with a $14.00 price target.</p>

Tip Ranks

Shattuck Labs

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Incyte

Agios Pharmac

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

SL-325 Data Catalysts and Phase 2 Launch Plans Underpin Buy Rating on Shattuck Labs